My assumptions concerning the name change....------------------------I believe the name change will allow the company to identify more closely with healthcare. Thus, the new acquisition - Canntx Life Science confirms the medical direction chosen by the company. Perhaps the Starseed name will no longer be required .... ex Pfizer has only one ID ....--------------------- Scorsis has mentioned many times that he wants the company to establish itself in the USA via only the medical field in order to serve the 2.0M members of Liuna. The company is currently working on this project and operations could begin in 2022. It all depends on how quickly government licenses are obtained. ------------------------ Perhaps this is why the projected revenues are in the order of $ 100M in 2022.------------------------------ Finally, there are 2 other territories which interest the company from a medical point of view: U.K. as well as Germany. It is a question of being patient ... but, it is for later ------------------------------------------- However, I could be wrong ...